Monica Torres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Monica Torres has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Etty Bachar-Wikstrom
Dermatology and Venereology Division, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden
2 shared publications - Jakob D. Wikstrom
Dermatology and Venereology Division, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden
2 shared publications - Ritu Bansal
Dermatology and Venereology Division, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden
2 shared publications - Craig Edward Wheelock
Unit of Integrative Metabolomics Institute of Environmental Medicine Karolinska Institutet Stockholm Sweden
1 shared publication - Farydah Inuossa
Dermatology and Venereology Division, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden
1 shared publication Gilad Silberberg
Bioinformatics & Computational Biology Research Operations, Champions Oncology Inc, Rehovot, Israel
1 shared publication
Latest Publications
- Open Access
- 26 July 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (9) , 1986-2001
Dantrolene corrects cellular disease features of Darier disease and may be a novel treatment
Darier disease (DD) is a rare severe acantholytic skin disease caused by mutations in the ATP2A2 gene that encodes for the sarco/endoplasmic reticulum calcium ATPase isoform 2 (SERCA2). SERCA2 maintains endoplasmic reticulum calcium homeostasis by pumping calcium into the ER, critical for regulating cellular calcium dynamics and cellular function. To date, there is no treatment that specifically targets the disease mechanisms in DD. Dantrolene sodium (Dl) is a ryanodine receptor antagonist that inhibits calcium release from ER to increase ER calcium levels and is currently used for non-dermatological indications. In this study, we first identified dysregulated genes and molecular pathways in DD patient skin, demonstrating downregulation of cell adhesion and calcium homeostasis pathways, as well as upregulation of ER stress and apoptosis. We then show in various in vitro models of DD and SERCA2 inhibition that Dl aided in the retention of ER calcium and promoted cell adhesion. In addition, Dl treatment reduced ER stress and suppressed apoptosis. Our findings suggest that Dl specifically targets pathogenic mechanisms of DD and may be a potential treatment.
- 26 July 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (9) , 1986-2001
Open AccessDantrolene corrects cellular disease features of Darier disease and may be a novel treatment
Darier disease (DD) is a rare severe acantholytic skin disease caused by mutations in the ATP2A2 gene that encodes for the sarco/endoplasmic reticulum calcium ATPase isoform 2 (SERCA2). SERCA2 maintains endoplasmic reticulum calcium homeostasis by pumping calcium into the ER, critical for regulating cellular calcium dynamics and cellular function. To date, there is no treatment that specifically targets the disease mechanisms in DD. Dantrolene sodium (Dl) is a ryanodine receptor antagonist that inhibits calcium release from ER to increase ER calcium levels and is currently used for non-dermatological indications. In this study, we first identified dysregulated genes and molecular pathways in DD patient skin, demonstrating downregulation of cell adhesion and calcium homeostasis pathways, as well as upregulation of ER stress and apoptosis. We then show in various in vitro models of DD and SERCA2 inhibition that Dl aided in the retention of ER calcium and promoted cell adhesion. In addition, Dl treatment reduced ER stress and suppressed apoptosis. Our findings suggest that Dl specifically targets pathogenic mechanisms of DD and may be a potential treatment.
- Open Access
- 14 April 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (10) , 2039-2051.e10
Metabolic Reprogramming and Reliance in Human Skin Wound Healing
- 14 April 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (10) , 2039-2051.e10
Open AccessMetabolic Reprogramming and Reliance in Human Skin Wound Healing